search
Back to results

Metformin Versus Insulin in Gestational Diabetes

Primary Purpose

Gestational Diabetes

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
metformin
insulin
Sponsored by
Turku University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gestational Diabetes focused on measuring gestational diabetes, metformin, insulin

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Mothers with gestational diabetes who had at least twice plasma glucose at fasting > 5.4 mmol/L and/or 1 hour postprandial value > 7.7 mmol/L at 24 to 32 gestational weeks

Exclusion Criteria:

  1. Fasting glucose > 7.0 mmol/L or 1 hour postprandial plasma glucose > 11.0 mmol/L or Glycosylated hemoglobin A1c (HbA1c) > 7.0%
  2. Renal, hepatic or cardiac failure
  3. Pregestational use of metformin
  4. Pregnancy with multiple fetuses

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Metformin

    insulin

    Arm Description

    Metformin 500 mg 1-2 tablets twice daily according to plasma glucose values

    NPH insulin once or twice daily and/or insulin lispro or aspart according to preprandial and postprandial glucose values

    Outcomes

    Primary Outcome Measures

    Birth Weight Per Arm
    birth weight adjusted for gestational weeks expressed as standard deviation units using data from Finnish fetal growth charts in normal pregnancies

    Secondary Outcome Measures

    Pregnancy Induced Hypertension Per Arm
    Participants with pregnancy induced hypertension defined as blood pressure over 140/90 mmHg or increase in systolic blood pressure > 30 mmHg or diastolic blood pressure > 15 mmHg
    Maternal Weight Gain Per Arm
    Pre-eclampsia Per Arm
    Mode of Delivery Per Arm
    Gestational Weeks at Delivery Per Arm
    Induction of Delivery Per Arm
    Shoulder Dystocia Per Arm
    Neonatal Hypoglycemia Per Arm
    Neonatal Hyperbilirubinemia Per Arm
    Apgar Score at 5 Min After Delivery Per Arm
    Apgar score 0-10. 0-2 points from heart rate; 0-2 points for respiratory effort; 0-2 points for skin colour; 0-2 points for muscle tone; 0-2 points for reflex response. For all items the higher the value, the better the outcome
    Neonate Transfer to Intensive Care Unit Per Arm
    Child Outcome at 2 Years Per Arm
    neuropsychological and motor skills testing

    Full Information

    First Posted
    November 3, 2010
    Last Updated
    November 21, 2014
    Sponsor
    Turku University Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01240785
    Brief Title
    Metformin Versus Insulin in Gestational Diabetes
    Official Title
    Metformin Versus Insulin in Gestational Diabetes. A Randomized Controlled Single Center Trial.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    June 2006 (undefined)
    Primary Completion Date
    January 2011 (Actual)
    Study Completion Date
    December 2012 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Turku University Hospital

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Gestational diabetes is traditionally treated with insulin. Metformin is a peroral drug used worldwide in the treatment of type 2 diabetes and also in a few studies on patients with gestational diabetes. The investigators aim is to compare insulin and metformin in the treatment of gestational diabetes. The investigators hypothesis is that there is no difference between insulin and metformin treated mothers in the main outcome criteria (birth weight, neonatal complications).
    Detailed Description
    Gestational diabetes is traditionally treated with insulin. Metformin is a peroral drug used worldwide in the treatment of type 2 diabetes and also in a few studies on patients with gestational diabetes. The investigators aim is to compare insulin and metformin in the treatment of gestational diabetes. The investigators hypothesis is that there is no difference between insulin and metformin treated mothers in the main outcome criteria (birth weight, neonatal complications). The study was performed as a randomized controlled trial in one center, Turku University hospital using the non-inferiority design in June 2006 - December 2010. The final study population consisted of altogether 217 women, of whom 110 received metformin and 107 insulin.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Gestational Diabetes
    Keywords
    gestational diabetes, metformin, insulin

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    221 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Metformin
    Arm Type
    Active Comparator
    Arm Description
    Metformin 500 mg 1-2 tablets twice daily according to plasma glucose values
    Arm Title
    insulin
    Arm Type
    Active Comparator
    Arm Description
    NPH insulin once or twice daily and/or insulin lispro or aspart according to preprandial and postprandial glucose values
    Intervention Type
    Drug
    Intervention Name(s)
    metformin
    Other Intervention Name(s)
    Diformin retard 500 mg
    Intervention Description
    metformin 1 g twice daily or maximum tolerated dose less than 2 g daily
    Intervention Type
    Drug
    Intervention Name(s)
    insulin
    Other Intervention Name(s)
    Protaphane, Humalog
    Intervention Description
    subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
    Primary Outcome Measure Information:
    Title
    Birth Weight Per Arm
    Description
    birth weight adjusted for gestational weeks expressed as standard deviation units using data from Finnish fetal growth charts in normal pregnancies
    Time Frame
    delivery
    Secondary Outcome Measure Information:
    Title
    Pregnancy Induced Hypertension Per Arm
    Description
    Participants with pregnancy induced hypertension defined as blood pressure over 140/90 mmHg or increase in systolic blood pressure > 30 mmHg or diastolic blood pressure > 15 mmHg
    Time Frame
    up to on the average 40 weeks of gestation
    Title
    Maternal Weight Gain Per Arm
    Time Frame
    up to on the average 40 weeks of gestation
    Title
    Pre-eclampsia Per Arm
    Time Frame
    up to on the average 40 weeks of gestation
    Title
    Mode of Delivery Per Arm
    Time Frame
    delivery
    Title
    Gestational Weeks at Delivery Per Arm
    Time Frame
    delivery
    Title
    Induction of Delivery Per Arm
    Time Frame
    delivery
    Title
    Shoulder Dystocia Per Arm
    Time Frame
    delivery
    Title
    Neonatal Hypoglycemia Per Arm
    Time Frame
    0-24 h after delivery
    Title
    Neonatal Hyperbilirubinemia Per Arm
    Time Frame
    0-3 days after delivery
    Title
    Apgar Score at 5 Min After Delivery Per Arm
    Description
    Apgar score 0-10. 0-2 points from heart rate; 0-2 points for respiratory effort; 0-2 points for skin colour; 0-2 points for muscle tone; 0-2 points for reflex response. For all items the higher the value, the better the outcome
    Time Frame
    5 minutes after delivery
    Title
    Neonate Transfer to Intensive Care Unit Per Arm
    Time Frame
    0-5 days after delivery
    Title
    Child Outcome at 2 Years Per Arm
    Description
    neuropsychological and motor skills testing
    Time Frame
    2 years after birth

    10. Eligibility

    Sex
    Female
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Mothers with gestational diabetes who had at least twice plasma glucose at fasting > 5.4 mmol/L and/or 1 hour postprandial value > 7.7 mmol/L at 24 to 32 gestational weeks Exclusion Criteria: Fasting glucose > 7.0 mmol/L or 1 hour postprandial plasma glucose > 11.0 mmol/L or Glycosylated hemoglobin A1c (HbA1c) > 7.0% Renal, hepatic or cardiac failure Pregestational use of metformin Pregnancy with multiple fetuses
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Tapani Rönnemaa, MD, PhD
    Organizational Affiliation
    Professor, Chief Physician
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    34059525
    Citation
    Huhtala MS, Ronnemaa T, Pellonpera O, Tertti K. Cord serum metabolome and birth weight in patients with gestational diabetes treated with metformin, insulin, or diet alone. BMJ Open Diabetes Res Care. 2021 May;9(1):e002022. doi: 10.1136/bmjdrc-2020-002022.
    Results Reference
    derived
    PubMed Identifier
    32652973
    Citation
    Huhtala MS, Tertti K, Juhila J, Sorsa T, Ronnemaa T. Metformin and insulin treatment of gestational diabetes: effects on inflammatory markers and IGF-binding protein-1 - secondary analysis of a randomized controlled trial. BMC Pregnancy Childbirth. 2020 Jul 11;20(1):401. doi: 10.1186/s12884-020-03077-6.
    Results Reference
    derived
    PubMed Identifier
    30227169
    Citation
    Huhtala MS, Tertti K, Pellonpera O, Ronnemaa T. Amino acid profile in women with gestational diabetes mellitus treated with metformin or insulin. Diabetes Res Clin Pract. 2018 Dec;146:8-17. doi: 10.1016/j.diabres.2018.09.014. Epub 2018 Sep 15.
    Results Reference
    derived
    PubMed Identifier
    26439816
    Citation
    Pellonpera O, Ronnemaa T, Ekblad U, Vahlberg T, Tertti K. The effects of metformin treatment of gestational diabetes on maternal weight and glucose tolerance postpartum--a prospective follow-up study. Acta Obstet Gynecol Scand. 2016 Jan;95(1):79-87. doi: 10.1111/aogs.12788. Epub 2015 Nov 8.
    Results Reference
    derived
    PubMed Identifier
    24633859
    Citation
    Tertti K, Laine K, Ekblad U, Rinne V, Ronnemaa T. The degree of fetal metformin exposure does not influence fetal outcome in gestational diabetes mellitus. Acta Diabetol. 2014 Oct;51(5):731-8. doi: 10.1007/s00592-014-0570-6. Epub 2014 Mar 16.
    Results Reference
    derived

    Learn more about this trial

    Metformin Versus Insulin in Gestational Diabetes

    We'll reach out to this number within 24 hrs